XXII (22nd Century Group) Gross Profit Margin

Corporate emblem and logo of xxiicentury.com (XXII)

22nd Century Group (XXII) is a biotech developer of low-nicotine tobacco, protected by unique patents and FDA approval. Gross profit margins demonstrate the efficiency of the model, where the current mark is -11.10. Moderate business growth relies on seed licensing, while the development of the R&D pipeline ensures a steady expansion of the raw material base for commercial product supplies.

XXII - xxiicentury.com Return on Gross Profit over the range 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company 22nd Century (XXII)

Summary company analysis:XXII 22nd Century Group, Inc.
Manufactured product of 22nd Century Group Inc.

An objective assessment of the investment attractiveness of 22nd Century Group (XXII) requires a deep fundamental analysis of production efficiency. Gross margin measures the profit share after deducting direct costs, allowing monthly gross margin data to serve as a gauge of the business's ability to control expenses. For an issuer monetizing proprietary low-nicotine raw materials, growth in this metric confirms the high market value of its biotechnologies and the quality of the generated capital.